SAN DIEGO, July 31, 2018 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that its portfolio of companies 2018 revenue has surpassed its total 2017 revenue.

“Our company is growing larger and faster than we could have ever imagined,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We’re happy to not only see our company entering new markets and revenue increasing exponentially every month, but it’s also been rewarding to see how we’ve become a major contributor to the expanding global support of cannabis.”

Medical Marijuana, Inc. is a major producer of cannabidiol (CBD) products in the U.S., Europe, Latin America and, as the company announced just last month, is expanding to Canada. Its distribution subsidiaries Kannaway®, HempMeds®, Dixie Botanicals, and Phyto Animal Health provide customers with a variety of oral, topical and edible CBD products that are Triple Lab Tested to ensure the highest standard of quality and consistency.

“We’re excited to share this success with our large network of supporters, investors and customers,” said Medical Marijuana, Inc. COO Blake Schroeder. “We’re proud to be at the forefront of the fast-growing movement for natural health and wellness and set the standard for CBD products throughout the world.”

Medical Marijuana, Inc. recently announced that its Q1 2018 revenues exceeded $10.5 million, an increase of more than 190% over Q1 2017. Wholly owned subsidiary Kannaway® saw the most growth from Q1 2017 to Q1 2018, with Q1 2018 revenues increasing more than 325% to $7.5 million.

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.